BSECompany Update4d ago · 16 Oct 2026, 02:55 pm

As per the file enclosed.

Venus Remedies Ltd · 526953

✦ AI Summary▲ PositiveExpansion

Venus Remedies Ltd has secured five marketing authorisations across four key international markets, including Kazakhstan, Peru, Kuwait, and Argentina, expanding its international presence and access to its pharmaceutical portfolio.

Analysis Scores

Earnings Impact2/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact6/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Venus Remedies Ltd - 526953 - Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets

Attachments (1)

📄

82d143e3-bfc3-4f09-af44-e9cb60379126.pdf

pdf

Download →
View document text
VENUS 6nioy grinoualions VRL/SEC/EXCHANGE 16,10.2026 Sub. : Venus Remedies Secures Five Marketing Authorisations Across Four Key International Markets. Dear Sir/ Madam, This is to inform you that Venus Remedies Limited has secured five marketing authorisations across Kazakhstan, Peru, Kuwait and Argentina, strengthening its international presence and expanding access to its pharmaceutical portfolio across key global markets. The approval§ cover Vancomycin and Fluorouracil in Kazakhstan, Fulvestrant in Peru, Methotrexate in Kuwait, and Meropenem in Argentina. The authorisations span markets across the CIS region, Latin America and the Middle East. "These marketing authorisations mark another step in strengthening our international presence and expanding our product reach across diverse markets. We remain focused on building a strong global portfolio and making quality pharmaceutical solutions accessible to more patients worldwide," said Saransh Chaudhary, Executive Director, Venus Remedies Ltd, and CEO, Venus Medicine Research Centre OwRC), The company has a continued focus on expanding its portfolio for exports across geographies and building opportunities for sustainable international growth. A leader in critical-care injectables, Venus Remedies has already established an international footprint in over 100 countries. "Our international growth strategy is centred on expanding our reach in high-potential markets while strengthening our product portfolio. We are committed to pursuing new opportunities through regulatory excellence, differentiated offerings and a sustained focus on global market expansion," said Aditi K. Chaudhary, President, International Business, Venus Remedies Ltd. Thanking you. Yours faithfully, for VENUS REMEDIES LllvllTED Neha (Company Secretary) M. No. F8374 VENUS REMEDIES LIMITED C®rp®mt. omc. : Unit-I : 51-52, Industrial Area, Phase-I, Panchkula (Hry.) ::,-.52J#|u7S!F2g3%g;#;::-6,9ETFcexT+I;|T|¥2'-23:!!:6'ndia 134113, India Regd. Ofnce : t'rit.n : Hill Top lndustnal Estate, Jharmajri EPIP, Pha8€-I, (Extn.), SCO 857, Cabin No.10, 2nd Floor, NAG, Manimajra, Bhatoli Kalan, Baddi (H.P.) 173205, India Chandigarh (U.T.) 160101, India Tcl. : +91-1792-242100. 242101 Website : www.venusremedies.com www.vmrcindia.com Uult-V : ©#F#q email : info©renusremedies.com VENUS PHARMA GmbH wh th gr AM Bahnhof I-3, D-59368, CIN No. ; L2`lco2CH1989PLC`009705 Weme, Germany Dun cusTON§